TY - JOUR
T1 - Preventing renal and cardiovascular risk by renal function assessment
T2 - Insights from a cross-sectional study in low-income countries and the USA
AU - Cravedi, Paolo
AU - Sharma, Sanjib Kumar
AU - Bravo, Rodolfo Flores
AU - Islam, Nazmul
AU - Tchokhonelidze, Irma
AU - Ghimire, Madhav
AU - Pahari, Bishnu
AU - Thapa, Sanjeev
AU - Basnet, Anil
AU - Tataradze, Avtandil
AU - Tinatin, Davitaia
AU - Beglarishvili, Lela
AU - Fwu, Chyng Wen
AU - Kopp, Jeffrey B.
AU - Eggers, Paul
AU - Ene-Iordache, Bogdan
AU - Carminati, Sergio
AU - Perna, Annalisa
AU - Chianca, Antonietta
AU - Couser, William G.
AU - Remuzzi, Giuseppe
AU - Perico, Norberto
PY - 2012
Y1 - 2012
N2 - Objective: To assess the prevalence of microalbuminuria and kidney dysfunction in lowincome countries and in the USA. Design: Cross-sectional study of screening programmes in five countries. Setting: Screening programmes in Nepal, Bolivia, the USA (National Health and Nutrition Examination Survey (NHANES) 2005-2008) Bangladesh and Georgia. Participants: General population in Nepal (n=20 811), Bolivia (n=3436) and in the USA (n=4299) and highrisk subjects in Bangladesh (n=1518) and Georgia (n=1549). Primary and secondary outcome measures: Estimated glomerular filtration rate (eGFR)<60ml/min/1.73 m 2 and microalbuminuria (defined as urinary albumin creatinine ratio values of 30-300 mg/g) were the main outcome measures. The cardiovascular (CV) risk was also evaluated on the basis of demographic, clinical and blood data. Results: The prevalence of eGFR<60ml/min/1.73 m2 was 19%, 3.2% and 7% in Nepal, Bolivia and the USA, respectively. In Nepal, 7% of subjects were microalbuminuric compared to 8.6% in the USA. The prevalence of participants with predicted 10-year CV disease (CVD) risk ≥10% was 16.9%, 9.4% and 17% in Nepal, Bolivia and in the USA, respectively. In Bangladesh and Georgia, subjects with eGFR<60 ml/min/1.73 m2 were 8.6% and 4.9%, whereas those with microalbuminuria were 45.4% and 56.5%, respectively. Predicted 10-year CVD risk ≥10% was 25.4% and 25% in Bangladesh and Georgia, respectively. Conclusions: Renal abnormalities are common among low-income countries and in the USA. Prevention programmes, particularly focused on those with renal abnormalities, should be established worldwide to prevent CVD and progression to end-stage renal disease.
AB - Objective: To assess the prevalence of microalbuminuria and kidney dysfunction in lowincome countries and in the USA. Design: Cross-sectional study of screening programmes in five countries. Setting: Screening programmes in Nepal, Bolivia, the USA (National Health and Nutrition Examination Survey (NHANES) 2005-2008) Bangladesh and Georgia. Participants: General population in Nepal (n=20 811), Bolivia (n=3436) and in the USA (n=4299) and highrisk subjects in Bangladesh (n=1518) and Georgia (n=1549). Primary and secondary outcome measures: Estimated glomerular filtration rate (eGFR)<60ml/min/1.73 m 2 and microalbuminuria (defined as urinary albumin creatinine ratio values of 30-300 mg/g) were the main outcome measures. The cardiovascular (CV) risk was also evaluated on the basis of demographic, clinical and blood data. Results: The prevalence of eGFR<60ml/min/1.73 m2 was 19%, 3.2% and 7% in Nepal, Bolivia and the USA, respectively. In Nepal, 7% of subjects were microalbuminuric compared to 8.6% in the USA. The prevalence of participants with predicted 10-year CV disease (CVD) risk ≥10% was 16.9%, 9.4% and 17% in Nepal, Bolivia and in the USA, respectively. In Bangladesh and Georgia, subjects with eGFR<60 ml/min/1.73 m2 were 8.6% and 4.9%, whereas those with microalbuminuria were 45.4% and 56.5%, respectively. Predicted 10-year CVD risk ≥10% was 25.4% and 25% in Bangladesh and Georgia, respectively. Conclusions: Renal abnormalities are common among low-income countries and in the USA. Prevention programmes, particularly focused on those with renal abnormalities, should be established worldwide to prevent CVD and progression to end-stage renal disease.
UR - http://www.scopus.com/inward/record.url?scp=84869786439&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2012-001357
DO - 10.1136/bmjopen-2012-001357
M3 - Article
AN - SCOPUS:84869786439
SN - 2044-6055
VL - 2
JO - BMJ Open
JF - BMJ Open
IS - 5
M1 - e001357
ER -